Daclizumab acts through ?: (A) cGMP activation, (B) Adenylcyclase inhibition, (C) IL 2 receptor blocker, (D) IL10 receptor blocker
Answer is C. Ans. is 'c' i.e., IL 2 receptor blocker Monoclonal antibodies (daclizumab and basiliximab) that block the interleukin 2 receptor and are used in prevention of graft rejection as immunosuppresant.